Heart Failure, Diastolic Clinical Trial
Official title:
Mechanisms and Management of Exercise Intolerance in Older Heart Failure Patients With Preserved Ejection Fraction
Heart failure with preserved ejection fraction (HFpEF) is the fastest growing form of heart failure with a high morbidity and mortality rate, and is associated with severe exercise intolerance. The mechanisms responsible for the reduced exercise tolerance remain poorly understood. The investigators propose a novel paradigm shift, focusing on peripheral limitations to exercise. In particular, the investigators will test the hypothesis that muscle sympathetic nerve activity (MSNA) is elevated in older HFpEF patients compared to healthy controls, and is associated with reduced exercise tolerance. The investigators will also test whether 16-weeks of exercise training will lower MSNA compared to attention control, and correlate with improved exercise tolerance in older HFpEF patients.
Heart failure with preserved ejection fraction is the fastest growing form of heart failure,
is almost exclusively found in older persons, particularly older women, and is associated
with a high morbidity and mortality rate. The primary chronic symptom in HFpEF patients is
severe exercise intolerance measured objectively as decreased peak exercise oxygen uptake
(peak VO2). A consequence of the reduced exercise tolerance is that activities of daily
living require near maximal effort, resulting in further deconditioning and reduced quality
of life. The majority of work to date has focused on cardiac limitations, showing impaired
cardiac output and marked diastolic dysfunction. Although these findings have provided
important insight into the pathophysiology of HFpEF, drug therapies targeting cardiac
function do not improve peak VO2, quality of life, or survival in HFpEF patients.
Older HFpEF patients have multiple skeletal muscle abnormalities including reduced skeletal
muscle oxidative capacity and capillary-to-fiber ratio resulting in increased anaerobic
metabolism during low-level exercise. Importantly, accumulation of anaerobic metabolites
within the exercising muscles are known to activate skeletal muscle afferent fibers (called
metaboreceptors), that elicit a reflex-mediated increase in efferent muscle sympathetic
(vasoconstrictor) nerve activity (MSNA). The investigators here propose a novel paradigm of
exercise intolerance in older HFpEF patients whereby skeletal muscle abnormalities lead to
overactivation of the muscle metaboreflex and MSNA mediated vasoconstriction that limits
delivery of oxygenated blood to the active muscles. Further, exercise training mediated
improvements in skeletal muscle function will alleviate the metaboreflex, thereby reducing
MSNA and improve oxygen delivery to the contracting muscles.
To test this novel paradigm, the investigators will first perform an initial cross-sectional
comparison of older (≥60 years) HFpEF patients (N=24) with age and sex-matched healthy
controls (N=24), and then enter the HFpEF patients into a randomized, controlled, single
blind, trial of exercise training to test the following hypothesis: (i) that MSNA is elevated
in older HFpEF patients compared to healthy controls, and is associated with reduced peak
VO2, physical functional performance, aerobic endurance, muscle blood flow, and quality of
life; and (ii) Exercise training will attenuate MSNA compared to attention control, and will
correlate with improved peak VO2, physical functional performance, aerobic endurance, muscle
blood flow, and quality of life in older HFpEF patients.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Enrolling by invitation |
NCT04573166 -
Personalized Atrial Septostomy for Heart Failure
|
N/A | |
Recruiting |
NCT02425371 -
Optimized Management of Comorbidity in Heart Failure With Preserved Ejection Fraction in the Elderly (>60 Years)
|
Phase 3 | |
Terminated |
NCT03312387 -
Muscle, Essential Amino Acids, and eXercise in Heart Failure
|
N/A | |
Completed |
NCT05475028 -
Network Medicine Approaches to Classify Heart Failure With PReserved Ejection Fraction by Signatures of DNA Methylation and Point-of-carE Risk calculaTors (PRESMET)
|
||
Recruiting |
NCT04950218 -
The Psoriasis Echo Study
|
||
Completed |
NCT02334891 -
Kyoto Congestive Heart Failure Study
|
||
Recruiting |
NCT05577819 -
Prevalence and Prediction of ATTR in Ambulatory Patients With HFpEF
|
N/A | |
Completed |
NCT05139472 -
Impact of Empagliflozin on Functional Capacity in Heart Failure With Preserved Ejection Fraction
|
Phase 3 | |
Recruiting |
NCT04682704 -
The Effect of Different Low-Level Tragus Stimulation Parameters On Autonomic Nervous System Function
|
N/A | |
Completed |
NCT03924479 -
Respiratory Muscle Function in Heart Failure
|
N/A | |
Recruiting |
NCT03830957 -
Efficacy and Safety of Ivabradine to Reduce Heart Rate Prior to Coronary CT-angiography in Advanced Heart Failure: Comparison With β-Blocker
|
N/A | |
Completed |
NCT02589977 -
Myocardial Perfusion, Oxidative Metabolism, and Fibrosis in HFpEF
|
Phase 4 | |
Completed |
NCT02946476 -
Prognostic Impact of Noncardiac Comorbidities in Heart Failure Patients
|
N/A | |
Recruiting |
NCT04179643 -
NAN-101 in Patients With Class III Heart Failure
|
Phase 1 | |
Recruiting |
NCT05425459 -
RESPONDER-HF Trial
|
N/A | |
Completed |
NCT04940312 -
MyoMobile Study: App-based Activity Coaching in Patients With Heart Failure and Preserved Ejection Fraction
|
||
Recruiting |
NCT04602338 -
Diagnosis and OutcoMes evaluAtIoN of Multicenter Patients With HFpEF Using Multimodality Imaging
|
||
Completed |
NCT03240237 -
CCM in Heart Failure With Preserved Ejection Fraction
|
N/A | |
Recruiting |
NCT05887271 -
A Randomised, Controlled Trial of a Low-energy Diet for Improving Functional Status in Heart Failure With PRESERVED Ejection Fraction Preserved Ejection Fraction
|
Phase 2/Phase 3 | |
Recruiting |
NCT05479669 -
Value of Intense Phenotyping in Heart Failure With Preserved Ejection Fraction
|